Summary
Eli Lilly and Company reported strong revenue growth in the first quarter of 2019, with a total of $5.1 billion, a 3% increase year-over-year. This growth was primarily driven by increased volume across key products like Trulicity, Taltz, and Basaglar, offsetting some pricing pressures. The company also completed the significant disposition of its remaining stake in Elanco Animal Health, recognizing a substantial gain and impacting net income positively. Despite revenue growth, net income from continuing operations saw a significant decrease of 52% to $561.1 million. This was largely due to increased investments in research and development and marketing, as well as substantial charges related to the acquisition of Loxo Oncology. The acquisition of Loxo, valued at $6.92 billion, is expected to bolster Lilly's oncology pipeline with promising investigational medicines. Investors should monitor the impact of patent expirations on key products like Alimta and Forteo, as well as ongoing legal and regulatory matters, which could affect future financial performance.
Financial Highlights
53 data points| Revenue | $5.09B |
| Cost of Revenue | $1.14B |
| Gross Profit | $3.95B |
| R&D Expenses | $1.23B |
| SG&A Expenses | $1.52B |
| Operating Expenses | $2.75B |
| Interest Expense | $86.50M |
| Net Income | $4.24B |
| EPS (Basic) | $4.33 |
| EPS (Diluted) | $4.31 |
| Shares Outstanding (Basic) | 979.90M |
| Shares Outstanding (Diluted) | 984.00M |
Key Highlights
- 1Revenue increased by 3% to $5.1 billion, driven by higher product volumes for key drugs like Trulicity, Taltz, and Basaglar.
- 2Completed the disposition of remaining Elanco Animal Health stake, recognizing a significant gain of $3.7 billion.
- 3Acquired Loxo Oncology for $6.92 billion, adding promising investigational medicines to its pipeline, particularly in oncology.
- 4Net income from continuing operations decreased by 52% to $561.1 million, impacted by increased R&D, marketing expenses, and acquisition-related charges.
- 5Significant charges of $423.9 million were recognized due to the Loxo acquisition, primarily related to employee equity awards.
- 6Continued vigilance is required regarding patent expirations for key products such as Alimta and Forteo, which are facing generic competition.
- 7The company is actively managing foreign currency risks and facing ongoing trends in pharmaceutical pricing and reimbursement, particularly in the U.S.